German MedTech company apoQlar received FDA 510(k) Class II clearance for its mixed reality software platform, VSI HoloMedicine. As a result, the US is the 30th country that apoQlar received medical certification in and will begin distribution of the device for clinical use starting in Florida from Q2 2023 onwards. 

Along with this, the company also started a Series A funding campaign to raise funds that will be used to further develop VSI HoloMedicine. 

apoQlar’s VSI HoloMedicine platform leverages the Microsoft HoloLens hardware to convert medical images and clinical workflows into immersive 3D holograms. This allows surgeons to plan the surgical procedure in 3D and visualize medical data. Currently, the platform is available in the EU and Singapore and can be used across medical fields such as oncology, urology, orthopedics, and cardiology. 

Analyst QuickTake : XR-based solutions for healthcare are booming and mainly pertain to training and remote visualization related to surgeries. Sweden-based Mentice recently raised SEK 3 million to improve the synthetic image generation and realism in its virtual reality software for healthcare professionals. This was followed by Augmedit’s EUR 1 million (~USD 1 million) seed funding round to obtain CE certification and FDA clearance for its products and to expand into new verticals (outside of neurosurgery) in both Europe and the US.